MB21D2

Across TCGA pan-cancer cohorts, MB21D2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MB21D2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MB21D2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MB21D2 is over-expressed in tumor.

HNSC, PDAC, and LSCC are the cancer types where MB21D2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MB21D2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.767	<.001	11	view →
PDAC	Female	II,III,IV	+0.580	<.001	7	view →
LSCC	Male	All	+0.321	<.001	7	view →
CCRCC	Male	All	+0.163	<.001	3	view →
COAD	All	IV	+0.498	.014	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MB21D2–HNSC

Open the HNSC breakdown →